3 results
Approved WMOCompleted
To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…
Approved WMOCompleted
The goal of this investigation is to show that Hemospray is effective in achieving initial hemostasis rates equivalent to standard of care treatment and a decreased rate of further bleed when compared to standard of care up to 72 hours after…
Approved WMOCompleted
The purpose of this studie is to evaluate the bioequivalence of canagliflozin.